Glaxosmithkline Share News (GSK)

Haleon announces results for exchange offers from GSK spin-off

(Alliance News) - Haleon PLC on Monday announced the pricing for offers to exchange six series of outstanding unregistered notes issued by GSK Consumer Healthcare Capital US LLC and one series by GSK Consumer Healthcare Capital UK PLC due between 2024 and 2052, which Haleon announced on September 29.

LONDON MARKET CLOSE: Eyes on BoE decision; NatWest drags down FTSE 100

(Alliance News) - Stocks in London closed in the red on Friday, but clung on for week gains, as interest rate decisions from the Bank of England and the US Federal Reserve move into focus.

GSK rises as EMA gives nod to RSV, HIV candidates

(Sharecast News) - Shares in pharmaceuticals giant GSK were in the green on Friday morning, after the European Medicines Agency (EMA) accepted marketing authorisation applications for RSV and HIV.

TOP NEWS: GSK gets support from European panel for HIV prevention

(Alliance News) - GSK PLC on Friday said its majority owned ViiV Healthcare venture has received the European Medicines Agency's validation for its marketing authorisation application for HIV prevention, and said its MAA for respiratory syncytial virus adult vaccine has also been accepted.

US FDA advisory panel votes against GSK kidney drug use in some cases

(Alliance News) - GSK PLC on Thursday said a US Food & Drug Administration panel has supported daprodustat for adults on dialysis but not for non-dialysis adults, and provided an update on the ContRAst phase III programme for otilimab.

GSK abandons regulatory submissions of rheumatoid arthritis drug

(Sharecast News) - Drugmaker GSK revealed on Thursday that it will not proceed with regulatory submissions of its experimental treatment for moderate-to-severe rheumatoid arthritis after the drug candidate failed to meet a key endpoint in a recent study.

UK earnings, trading statements calendar - next 7 days

IN BRIEF: Sareum widens annual loss; considers future of SRA737

Sareum Holdings PLC - Cambridge, England-based drug developer for cancer and autoimmune diseases - In the year ended June 30, pretax loss widens to GBP2.6 million from GBP1.7 million a year before. No revenue is recorded in either year, but in the previous year it brought in GBP171,000 in other operating income, with none recorded for financial 2022. Says it will discuss the future of SRA737 with partner Cancer Research Technology Pioneer Fund. Earlier this month, GSK PLC subsidiary Sierra Oncology Inc said it intends to return the rights for the SRA737 cancer treatment to CPF.

GSK says respiratory vaccine candidate accepted for review in Japan

(Alliance News) - GSK PLC on Friday said that a new drug application for its respiratory syncytial virus vaccine candidate has been accepted for review by the Japanese Ministry of Health, Labour & Welfare.

GSK seeks Japanese approval for respiratory disease vaccine

(Sharecast News) - Japan's medicines regulator has agreed to review GSK's vaccine candidate for respiratory disease, the UK drugs group said on Friday.

TOP NEWS: GSK hails Menveo vaccine approval in one-vial presentation

(Alliance News) - GSK PLC on Monday said the meningitis vaccine Menveo has been approved by the US Food & Drug Administration in a single-vial presentation to help prevent disease caused by meningococcal bacteria serogroups A, C, Y, and W.

GlaxoSmithKline receives FDA approval for new presentation of Menveo asset

(Sharecast News) - Drugmaker GlaxoSmithKline has received Food and Drug Administration approval for a new presentation of its invasive meningococcal disease vaccine.

LONDON BROKER RATINGS: Peel Hunt likes Petrofac; Deutsche cuts boohoo

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

TOP NEWS: GSK hails vaccine success for severe virus in older people

(Alliance News) - GSK PLC on Thursday announced a vast decline in severe respiratory syncytial virus, or RSV, disease among people aged 60 years and older who were vaccinated with its RSV vaccine candidate.

RSV vaccine race heats up with highly effective GSK shot

LONDON, Oct 13 (Reuters) - Data unveiled on Thursday showed GSK's respiratory syncytial virus (RSV) vaccine was 82.6% effective in a keenly watched late-stage study involving older adults.